Acknowledgments
Chapter 1 Introduction: The Psychedelic Renaissance
Continues
Michael Winkelman and Ben Sessa
Part One Psychiatry
Chapter 2 Psychedelics and Psychiatry: A New Treatment Model
for the 21st Century
Charles S. Grob and Gary Bravo
Chapter 3 Therapeutic Applications of
3,4-methylenedioxymethamphetamine (MDMA)
Ben Sessa
Chapter 4 Psilocybin Therapy for Major Depressive
Disorder
James JH Rucker
Chapter 5 Ketamine Therapy for Treatment-Resistant
Depression
L. Alison McInnes and Marc Ettensohn
Chapter 6 Evidence for the Therapeutic Effects of
Ayahuasca
Dráulio Barros de Araújo
Part Two Substance Abuse
Chapter 7 Psilocybin for the Treatment of Substance Use
Disorders
Ishani Rao and Greg Lydall
Chapter 8 Potential Applications of Cannabis and
Cannabinoids in the Treatment of Substance Use Disorder and in Harm
Reduction
José Carlos Bouso, Rafael Guimaraes dos Santos, and Jaime
Hallak
Chapter 9 Psychedelic Therapy as a Complementary Treatment
Approach for Alcohol Use Disorders
Peter Eischens and William Leigh Atherton
Part Three Medical Hypotheses
Chapter 10 Effects of Psychedelics on Inflammation and
Immunity
Attila Szabo
Chapter 11 The Protective Role of Dimethyltryptamine against
Ischemia-Reperfusion Injury
Ede Frecska, Attila Istvan Kovacs, and Attila Szabo
Chapter 12 Psychedelic Treatment of Disruptive Personality
Patterns
Petr Winkler and Rita Kocárová
Part Four Treatment and Training
Chapter 13 Guidelines in Applying Psychedelic Therapies
Friederike Meckel
Chapter 14 Training Psychedelic Therapists
Janis Phelps
Part Five Societal Engagement with Psychedelics
Chapter 15 Community-Based Full-Spectrum Harm Reduction
Approaches When Caring for Psychoactive- and Psychedelic-Related
Problems at a Transformational Festival
Maria Carmo Carvalho, Cristiana Vale Pires, Ana Luísa Costa, Daniel
Martins, Helena Valente, Inês Macedo, Paula Frango, and Raquel
Lira
Chapter 16 Microdosing Psychedelics
James Fadiman and Sophia Korb
Chapter 17 Bringing Psychedelics and Entactogens into
Mainstream Pharmaceuticals: A Focus on MDMA
Anne C. Wagner, Michael C. Mithoefer, and Rick Doblin
About the Editors and Contributors
Index
Researchers, program administrators, and practicing clinicians explain the most recent developments in using psychedelic substances to treat psychological, physiological, and social problems.
Michael Winkelman, PhD, is retired from the School of
Human Evolution and Social Change at Arizona State University,
where he served as director of the medical anthropology
program.
Ben Sessa, MD, is a consultant child and adolescent
psychiatrist working in adult addiction services and with PTSD in
veterans.
Recommended. All readers.
*Choice*
![]() |
Ask a Question About this Product More... |
![]() |